AI Spending in Healthcare and Wellness Triples as Personalized Wellness Platforms Scale November 25, 2025 - Baystreet.ca Issued on behalf of Aleen Inc. VANCOUVER – Baystreet.ca News Commentary – Healthcare's artificial intelligence transformation is accelerating at unprecedented speed, with AI spending hitting $1.4 billion this year, nearly tripling 2024's investment as organizations race to capture efficiency gains and improve patient outcomes[1]. Simultaneously, physician adoption of AI tools has surged from 38% to 66% in just one year, signaling a fundamental shift in how healthcare professionals and consumers interact with digital health platforms[2]. This convergence of institutional investment and grassroots adoption is creating exceptional opportunities for companies building AI-driven wellness infrastructure. Among those positioned to benefit are Aleen Inc. (CSE: ALEN-U), Certara, Inc. (NASDAQ: CERT), OptimizeRx Corp. (NASDAQ: OPRX), Cognizant Technology Solutions Corporation (NASDAQ: CTSH), and OmniAb, Inc. (NASDAQ: OABI). Industry analysts project the global digital health and wellness market will surge from $607 billion in 2025 to $3.57 trillion by 2034, representing annual growth exceeding 21%[3]. With consumers increasingly demanding AI-powered personalization for their health management, and 34% already using artificial intelligence to streamline wellness decisions, companies offering data-driven insights and intelligent analytics are entering a period of exceptional demand[4]. Aleen Inc. (CSE: ALEN-U), a Canadian digital wellness company, has announced the development of a personal account system designed to redefine how individuals interact with their wellness data. The upcoming personal account will serve as an intuitive hub where users can seamlessly upload, manage, and visualize their well-being information. "This is about giving people ownership of their wellness journey," said Oleksandr Luzin, Director of Aleen Inc. "We're creating a system that turns information into confidence — and privacy into empowerment." The company previously announced it was beginning early concept testing for smart wellness analytics, with research highlighting three recurring user expectations: clear visualization of personal wellness patterns, strong privacy safeguards and control over shared information, and simple, non-medical interpretation of structured inputs. "Our current focus is on understanding how an analytical tool can responsibly support everyday well-being — while staying entirely outside the realm of diagnostic or medical functions," said Anastasiia Kalashnik, PR Specialist of Aleen Inc. "We are laying the groundwork for a feature that inspires awareness and self-reflection, not prescribes actions." Based in Ontario, Aleen Inc. went public in June 2025 and has developed an AI platform designed to help users understand their inputs and wellness indicators. The company operates in a rapidly expanding market, with the global digital wellness sector currently valued at approximately $12.87 billion in 2025 and projected to grow to $45.65 billion by 2034, representing annual growth of 15.1%. With about 57% of consumers now using digital apps and wearable devices to monitor their well-being, Aleen Inc. is positioned to capture a portion of this expanding demand. The Aleen AI system can be accessed in two ways. Users can visit the Aleen website for free wellness insights, which helps raise awareness and encourages active engagement with personal well-being. Businesses can integrate Aleen Inc.'s technology via its API, allowing wellness apps and digital platforms to embed the AI-powered insights into their own services. The company generates revenue through its API offerings, available through a per-call option for businesses paying only for requests used, and a monthly subscription for consistent access. Looking ahead to 2026, Aleen Inc. plans to launch the personal user accounts currently in development alongside the smart analytics features being tested. To fund these initiatives, Aleen Inc. is currently seeking between $20 million and $30 million in strategic investment, with plans to allocate 35% toward technology development, 30% toward sales and marketing efforts, and 20% for product expansion including mobile apps and specialized modules for corporate wellness programs. With 12,643,300 common shares currently issued and outstanding, Aleen Inc. continues to build its presence in the digital wellness space under the leadership of CEO Inna Aksman. The company emphasizes that its platform is designed for preliminary wellness insights only and is not intended to replace consultations with healthcare professionals. Aleen Inc. does not provide medical diagnoses and is not regulated as a medical device by the FDA or other health authorities. CONTINUED… Read this and more news for Aleen Inc. at: https://usanewsgroup.com/2025/10/25/ai-engine-replaces-the-waiting-room-powering-the-660b-health-revolution/ Certara, Inc. (NASDAQ: CERT) has launched TFL Studio, the first cloud-native module of its Phoenix Cloud solution, enabling pharmacokinetic and pharmacodynamic scientists to create Tables, Figures, and Listings up to 50% faster. The platform addresses traditional workflow bottlenecks caused by manual processes and fragmented tools while ensuring consistency across regulatory submissions. "The introduction of TFL Studio marks a pivotal moment in our mission to bring advanced, cloud-native solutions to drug discovery and development," said William F. Feehery, CEO of Certara. A complementary module, AI PK Reports, will launch this quarter and leverages GenAI to transform tables, figures, and listings into draft PK reports in minutes rather than days. TFL Studio integrates with Certara's Integral data repository to provide a single source of truth for PK/PD data, models, and visualizations. OptimizeRx Corp. (NASDAQ: OPRX) delivered strong third quarter results with revenue increasing 22% year-over-year to $26.1 million while gross profit surged 30% to $17.5 million. The healthcare technology company achieved GAAP net income of $0.8 million and raised its full-year 2025 guidance to between $105 million and $109 million in revenue. "Year-to-date results reflect strong, profitable growth that continues to outperform expectations," said Stephen L. Silvestro, CEO of OptimizeRx. "This performance stems from our unwavering focus on execution, our commitment to delivering exceptional customer outcomes, the power of our market-leading patient identification technologies, and the expanding partnerships across our network." The company introduced fiscal year 2026 guidance projecting revenue between $118 million and $124 million with Adjusted EBITDA between $19 million and $22 million. OptimizeRx also paid off an incremental $2 million in principal from its term loan subsequent to quarter end. Cognizant Technology Solutions Corporation (NASDAQ: CTSH) is now using Anthropic's Claude to help enterprise customers and internal teams move from AI experimentation to scaled business outcomes. The company will deploy Claude to up to 350,000 associates across key corporate functions, engineering, and delivery teams while using Claude Code to accelerate coding tasks, testing, documentation, and DevOps workflows. "Enterprises are moving beyond simple productivity gains toward a more connected, agentic future," said Ravi Kumar S, CEO of Cognizant. "By pairing Anthropic's Claude models and agentic tooling with Cognizant's suite of platforms and industry expertise, we will help clients build the foundations of an agentified enterprise where intelligent systems collaborate with people to accelerate modernization, engineering and industry transformation." Initial focus areas include software engineering productivity, legacy modernization, and developing vertical solutions beginning with Financial Services. Cognizant plans to engage clients through workshops, reference patterns, and platform integrations to identify high-value use cases and move them into production. OmniAb, Inc. (NASDAQ: OABI) has signed a technology license and services agreement for antibody discovery with Mabtrx Biosciences, a wholly owned subsidiary of a joint venture between ArrowMark Partners and Viking Global Investors. The agreement focuses on OmnidAb single domain technology and provides OmniAb with revenue for discovery services as well as potential equity and royalties. "We're pleased to engage with ArrowMark and Viking and their latest NewCo as our newest technology and discovery services partner," said Matt Foehr, President and CEO of OmniAb. "This latest transaction highlights how we can leverage our novel transgenic chicken-based technologies to deliver value through multiple innovative strategies across different time horizons." OmniAb's platform uses proprietary engineered transgenic animals to create optimized antibody candidates for human therapeutics, which the company believes comprises the most diverse host systems available in the industry. The business model aligns scientific and economic interests through structured agreements that include upfront fees, service revenue, milestones, and royalties on commercial sales. Article Sources: https://usanewsgroup.com/2025/10/25/ai-engine-replaces-the-waiting-room-powering-the-660b-health-revolution/ CONTACT: Baystreet.ca [email protected] (805) 649-0042 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Aleen Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Aleen Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Aleen Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Aleen Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Aleen’s solutions operate within the wellness domain and are not subject to FDA or Health Canada approval. The platform provides wellness insights based on user inputs and is not intended to diagnose, treat, or prevent any medical condition. -- SOURCES CITED: 1. https://menlovc.com/perspective/2025-the-state-of-ai-in-healthcare/ 2. https://intuitionlabs.ai/articles/ai-adoption-us-hospitals-2025 3. https://www.towardshealthcare.com/insights/digital-health-and-wellness-market-sizing 4. https://nielseniq.com/global/en/insights/analysis/2025/the-role-of-technology-in-wellness-in-2025/
AI Spending in Healthcare and Wellness Triples as Personalized Wellness Platforms Scale November 25, 2025 - Baystreet.ca Issued on behalf of Aleen Inc. VANCOUVER – Baystreet.ca News Commentary – Healthcare's artificial intelligence transformation is accelerating at unprecedented speed, with AI spending hitting $1.4 billion this year, nearly tripling 2024's investment as organizations race to capture efficiency gains and improve patient outcomes[1]. Simultaneously, physician adoption of AI tools has surged from 38% to 66% in just one year, signaling a fundamental shift in how healthcare professionals and consumers interact with digital health platforms[2]. This convergence of institutional investment and grassroots adoption is creating exceptional opportunities for companies building AI-driven wellness infrastructure. Among those positioned to benefit are Aleen Inc. (CSE: ALEN-U), Certara, Inc. (NASDAQ: CERT), OptimizeRx Corp. (NASDAQ: OPRX), Cognizant Technology Solutions Corporation (NASDAQ: CTSH), and OmniAb, Inc. (NASDAQ: OABI). Industry analysts project the global digital health and wellness market will surge from $607 billion in 2025 to $3.57 trillion by 2034, representing annual growth exceeding 21%[3]. With consumers increasingly demanding AI-powered personalization for their health management, and 34% already using artificial intelligence to streamline wellness decisions, companies offering data-driven insights and intelligent analytics are entering a period of exceptional demand[4]. Aleen Inc. (CSE: ALEN-U), a Canadian digital wellness company, has announced the development of a personal account system designed to redefine how individuals interact with their wellness data. The upcoming personal account will serve as an intuitive hub where users can seamlessly upload, manage, and visualize their well-being information. "This is about giving people ownership of their wellness journey," said Oleksandr Luzin, Director of Aleen Inc. "We're creating a system that turns information into confidence — and privacy into empowerment." The company previously announced it was beginning early concept testing for smart wellness analytics, with research highlighting three recurring user expectations: clear visualization of personal wellness patterns, strong privacy safeguards and control over shared information, and simple, non-medical interpretation of structured inputs. "Our current focus is on understanding how an analytical tool can responsibly support everyday well-being — while staying entirely outside the realm of diagnostic or medical functions," said Anastasiia Kalashnik, PR Specialist of Aleen Inc. "We are laying the groundwork for a feature that inspires awareness and self-reflection, not prescribes actions." Based in Ontario, Aleen Inc. went public in June 2025 and has developed an AI platform designed to help users understand their inputs and wellness indicators. The company operates in a rapidly expanding market, with the global digital wellness sector currently valued at approximately $12.87 billion in 2025 and projected to grow to $45.65 billion by 2034, representing annual growth of 15.1%. With about 57% of consumers now using digital apps and wearable devices to monitor their well-being, Aleen Inc. is positioned to capture a portion of this expanding demand. The Aleen AI system can be accessed in two ways. Users can visit the Aleen website for free wellness insights, which helps raise awareness and encourages active engagement with personal well-being. Businesses can integrate Aleen Inc.'s technology via its API, allowing wellness apps and digital platforms to embed the AI-powered insights into their own services. The company generates revenue through its API offerings, available through a per-call option for businesses paying only for requests used, and a monthly subscription for consistent access. Looking ahead to 2026, Aleen Inc. plans to launch the personal user accounts currently in development alongside the smart analytics features being tested. To fund these initiatives, Aleen Inc. is currently seeking between $20 million and $30 million in strategic investment, with plans to allocate 35% toward technology development, 30% toward sales and marketing efforts, and 20% for product expansion including mobile apps and specialized modules for corporate wellness programs. With 12,643,300 common shares currently issued and outstanding, Aleen Inc. continues to build its presence in the digital wellness space under the leadership of CEO Inna Aksman. The company emphasizes that its platform is designed for preliminary wellness insights only and is not intended to replace consultations with healthcare professionals. Aleen Inc. does not provide medical diagnoses and is not regulated as a medical device by the FDA or other health authorities. CONTINUED… Read this and more news for Aleen Inc. at: https://usanewsgroup.com/2025/10/25/ai-engine-replaces-the-waiting-room-powering-the-660b-health-revolution/ Certara, Inc. (NASDAQ: CERT) has launched TFL Studio, the first cloud-native module of its Phoenix Cloud solution, enabling pharmacokinetic and pharmacodynamic scientists to create Tables, Figures, and Listings up to 50% faster. The platform addresses traditional workflow bottlenecks caused by manual processes and fragmented tools while ensuring consistency across regulatory submissions. "The introduction of TFL Studio marks a pivotal moment in our mission to bring advanced, cloud-native solutions to drug discovery and development," said William F. Feehery, CEO of Certara. A complementary module, AI PK Reports, will launch this quarter and leverages GenAI to transform tables, figures, and listings into draft PK reports in minutes rather than days. TFL Studio integrates with Certara's Integral data repository to provide a single source of truth for PK/PD data, models, and visualizations. OptimizeRx Corp. (NASDAQ: OPRX) delivered strong third quarter results with revenue increasing 22% year-over-year to $26.1 million while gross profit surged 30% to $17.5 million. The healthcare technology company achieved GAAP net income of $0.8 million and raised its full-year 2025 guidance to between $105 million and $109 million in revenue. "Year-to-date results reflect strong, profitable growth that continues to outperform expectations," said Stephen L. Silvestro, CEO of OptimizeRx. "This performance stems from our unwavering focus on execution, our commitment to delivering exceptional customer outcomes, the power of our market-leading patient identification technologies, and the expanding partnerships across our network." The company introduced fiscal year 2026 guidance projecting revenue between $118 million and $124 million with Adjusted EBITDA between $19 million and $22 million. OptimizeRx also paid off an incremental $2 million in principal from its term loan subsequent to quarter end. Cognizant Technology Solutions Corporation (NASDAQ: CTSH) is now using Anthropic's Claude to help enterprise customers and internal teams move from AI experimentation to scaled business outcomes. The company will deploy Claude to up to 350,000 associates across key corporate functions, engineering, and delivery teams while using Claude Code to accelerate coding tasks, testing, documentation, and DevOps workflows. "Enterprises are moving beyond simple productivity gains toward a more connected, agentic future," said Ravi Kumar S, CEO of Cognizant. "By pairing Anthropic's Claude models and agentic tooling with Cognizant's suite of platforms and industry expertise, we will help clients build the foundations of an agentified enterprise where intelligent systems collaborate with people to accelerate modernization, engineering and industry transformation." Initial focus areas include software engineering productivity, legacy modernization, and developing vertical solutions beginning with Financial Services. Cognizant plans to engage clients through workshops, reference patterns, and platform integrations to identify high-value use cases and move them into production. OmniAb, Inc. (NASDAQ: OABI) has signed a technology license and services agreement for antibody discovery with Mabtrx Biosciences, a wholly owned subsidiary of a joint venture between ArrowMark Partners and Viking Global Investors. The agreement focuses on OmnidAb single domain technology and provides OmniAb with revenue for discovery services as well as potential equity and royalties. "We're pleased to engage with ArrowMark and Viking and their latest NewCo as our newest technology and discovery services partner," said Matt Foehr, President and CEO of OmniAb. "This latest transaction highlights how we can leverage our novel transgenic chicken-based technologies to deliver value through multiple innovative strategies across different time horizons." OmniAb's platform uses proprietary engineered transgenic animals to create optimized antibody candidates for human therapeutics, which the company believes comprises the most diverse host systems available in the industry. The business model aligns scientific and economic interests through structured agreements that include upfront fees, service revenue, milestones, and royalties on commercial sales. Article Sources: https://usanewsgroup.com/2025/10/25/ai-engine-replaces-the-waiting-room-powering-the-660b-health-revolution/ CONTACT: Baystreet.ca [email protected] (805) 649-0042 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Aleen Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Aleen Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Aleen Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Aleen Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Aleen’s solutions operate within the wellness domain and are not subject to FDA or Health Canada approval. The platform provides wellness insights based on user inputs and is not intended to diagnose, treat, or prevent any medical condition. -- SOURCES CITED: 1. https://menlovc.com/perspective/2025-the-state-of-ai-in-healthcare/ 2. https://intuitionlabs.ai/articles/ai-adoption-us-hospitals-2025 3. https://www.towardshealthcare.com/insights/digital-health-and-wellness-market-sizing 4. https://nielseniq.com/global/en/insights/analysis/2025/the-role-of-technology-in-wellness-in-2025/